Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine the overall survival of patients with Stage IV
non-small cell lung cancer (NSCLC) treated with ISIS EIF4E Rx in combination with carboplatin
and paclitaxel.